GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2021-04-01| Asia-PacificR&D

Takeda to Pursue Hard-to-Drug Neurodegenerative Disease Targets with BridGene Biosciences

by Tyler Chen
Share To

Following its long-term research plan of focusing on neurological diseases, Japan’s Takeda has announced a collaboration with US pharmaceutical company BridGene Biosciences to initiate five hard-to-drug neurodegenerative disease programs and develop small molecule drugs. BridGene is eligible to receive over $500 Million in potential upfront and milestone payments.

 

Partnership to Identify Small Molecule for Undruggable Targets

The strategic partnership fits Takeda’s long-term research plan. The Japanese drugmaker will receive access to BridGene’s Chemoproteomics platform, namely IMTAC (Isobaric Mass Tagged Affinity Characterization), to identify undruggable targets and develop candidates along with clinical trials.

According to the Co-Founder and CEO of BridGene, Ping Cao, Ph.D., IMTAC employs covalent small molecules to bind to hard-to-drug targets and chemoproteomics to understand what facilitates the characteristics of disease onset and progression. The platform is able to identify the targets that a small molecule drug candidate interacts with.

 

Deal Terms

Under the agreement, the upfront payment is for access to IMTAC, and Takeda will be given exclusive rights to research, develop and commercialize up to five validated targets. The first research program would be finding targets that lead to a neurodegenerative disease phenotype that is modifiable by small molecules in a phenotypic screen. Then, Takeda can initiate an additional four programs.

With this collaboration, BridGene stands to receive over $500 million in milestone payments, including preclinical, clinical, and commercial milestones and royalties.

 

Collaboration with Anima

In mid-March, Takeda struck a deal with Anima Biotech, a small molecule biotech to develop three drugs for genetically-defined neurological diseases.

The cooperation involved Anima’s Translation Control Therapeutics platform that will strive to find novel mRNA translation modulators. Takeda will get the exclusive rights to develop and commercialize those candidates.

The collaboration includes Anima’s early Huntington’s Disease program against the huntingtin (HTT) target, selectively preventing the mutated protein with small molecules. Takeda can initiate two more neurological targets and have the option to add one more before a set date.

Anima will receive $120 million in upfront payments and up to $1.2 billion in milestone payments and royalties if Takeda added three research targets, or up to $1.1 billion if Takeda only manages two before the set date.

Related Article: After Five Year Oncology Alliance, Takeda Acquires Maverick to Embark on Solid Tumor Quest

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Alzheimer’s Drug LEQEMBI Approved for Treatment in Hong Kong
2024-07-12
FDA Greenlights Eli Lilly’s Groundbreaking Alzheimer’s Drug Kisunla for Early Symptomatic Treatment
2024-07-04
Autistic Individuals at Triple Risk for Parkinson’s-Like Symptoms, Study Finds
2024-05-30
LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top